Last reviewed · How we verify
1.5% Lidocaine
At a glance
| Generic name | 1.5% Lidocaine |
|---|---|
| Also known as | Lidocaine |
| Sponsor | The Second Affiliated Hospital of Chongqing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (PHASE4)
- Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars (NA)
- Microneedling for Burn Hypertrophic Scars (NA)
- Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP) (NA)
- Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty (PHASE4)
- Reducing Side-effects of Autologous Skin Tissue Harvesting (EARLY_PHASE1)
- Effect of Lidocaine on Hemodynamic Response and Postoperative Sore Throat (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1.5% Lidocaine CI brief — competitive landscape report
- 1.5% Lidocaine updates RSS · CI watch RSS
- The Second Affiliated Hospital of Chongqing Medical University portfolio CI